Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?GuruFocus · Oct 12, 2026
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PRNewsWire · Oct 12, 2026
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin DeficiencyGlobeNewsWire · Sep 15, 2026
Callio Therapeutics Appoints Zachary Hornby as Chief Executive OfficerGlobeNewsWire · Sep 9, 2026Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$1.06 | -$1.06 | Beat |
| May 8, 2026 | -$0.51 | -$0.60 | Miss |
| Mar 9, 2026 | -$0.44 | -$0.58 | Miss |
| Nov 5, 2025 | -$0.53 | -$0.62 | Miss |
| Aug 5, 2025 | -$0.75 | -$0.70 | Beat |
| May 9, 2025 | -$0.68 | -$0.71 | Miss |